Takeda receives approval for fruzaqla (fruquintinib) in japan for the treatment of unresectable advanced or recurrent colorectal cancer

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that it has received approval from the japanese ministry of health, labour and welfare to manufacture and market fruzaqla capsules 1mg/5mg (generic name: fruquintinib), a selective oral inhibitor of vascular endothelial growth factor receptor (vegfr) -1, -2 and -3, for the treatment of advanced or recurrent colorectal cancer (crc) that is neither curable nor resectable and that has progressed after chem.
TAK Ratings Summary
TAK Quant Ranking